Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy

Masaya Takahashi,Katsuyuki Takahashi,Kazuki Ogawa,Tsutomu Takashima,Yuka Asano,Shinichiro Kashiwagi,Satoru Noda,Naoyoshi Onoda,Masaichi Ohira,Katsuya Nagayama

Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy

2018

Masaya Takahashi
Katsuyuki Takahashi
Kazuki Ogawa
Tsutomu Takashima
Yuka Asano
Shinichiro Kashiwagi
Satoru Noda
Naoyoshi Onoda
Masaichi Ohira
Katsuya Nagayama

Purpose The purpose of this study was to compare the efficacy of the pre-prescription of garenoxacin mesylate hydrate (GRNX) with that of moxifloxacin hydrochloride (MFLX) in the management of breast cancer patients with low-risk febrile neutropenia.

Keywords:

Intensive care medicine
Breast cancer
Garenoxacin
Febrile neutropenia
Adjuvant
Medical prescription
Moxifloxacin hydrochloride
Medicine
Moxifloxacin
Internal medicine
Chemotherapy
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations